Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/85823
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Comparative assessment of PDE 4 and 7 inhibitors as therapeutic agents in experimental autoimmune encephalomyelitis |
Autor: | González-García, C.; Bravo, Beatriz; Ballester, A.; Gõmez-Pérez, R.; Eguiluz, César; Redondo, Miriam CSIC; Martínez Gil, Ana CSIC ORCID ; Gil, Carmen CSIC ORCID ; Ballester, S. | Fecha de publicación: | 2013 | Editor: | Nature Publishing Group | Citación: | British Journal of Pharmacology 170: 602- 613 (2013) | Resumen: | Background and Purpose PDE4 inhibition suppresses experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS). However, side effects hinder PDE4 inhibitors clinical use. PDE7 inhibition might constitute an alternative therapeutic strategy, but few data about the anti-inflammatory potential of PDE7 inhibitors are currently available. We have used the EAE model to perform a comparative evaluation of PDE4 and PDE7 inhibition as strategies for MS treatment. Experimental Approach Two PDE7 inhibitors, the sulfonamide derivative BRL50481 and the recently described quinazoline compound TC3.6, were assayed to modulate EAE in SJL mice, in comparison with the well-known PDE4 inhibitor Rolipram. We evaluated clinical signs, presence of inflammatory infiltrates in CNS and anti-inflammatory markers. We also analysed the effect of these inhibitors on the inflammatory profile of spleen cells in vitro. Key Results TC3.6 prevented EAE with efficacy similar to Rolipram, while BRL50481 had no effect on the disease. Differences between both PDE7 inhibitors are discussed. Data from Rolipram and TC3.6 showed that PDE4 and PDE7 inhibition work through both common and distinct pathways. Rolipram administration caused an increase in IL-10 and IL-27 expression which was not found after TC3.6 treatment. On the other hand, both inhibitors reduced IL-17 levels, prevented infiltration in CNS and increased the expression of the T regulator cell marker Foxp3. Conclusions and Implications These results provide new information about the effects of Rolipram on EAE, underline PDE7 inhibition as a new therapeutic target for inflammatory diseases and show the value of TC3.6 to prevent EAE, with possible consequences for new therapeutic tools in MS. © 2013 The British Pharmacological Society. | URI: | http://hdl.handle.net/10261/85823 | DOI: | 10.1111/bph.12308 | Identificadores: | doi: 10.1111/bph.12308 issn: 0007-1188 e-issn: 1476-5381 |
Aparece en las colecciones: | (IQM) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 15,38 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
20
checked on 11-abr-2024
SCOPUSTM
Citations
50
checked on 23-abr-2024
WEB OF SCIENCETM
Citations
48
checked on 23-feb-2024
Page view(s)
385
checked on 22-abr-2024
Download(s)
106
checked on 22-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
Artículos relacionados:
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.